Pipeline Overview

Innovative Drugs Designed to Improve Patients’ Lives

Our clinical-stage pipeline includes four internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies and solid tumors. It comprises both Targeted Protein Degraders to eliminate disease causing proteins and E3 ligase inhibitors that target key control elements in immune regulation (Targeted Protein Elevation). Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of Targeted Protein Degraders against a set of unique targets.

Drug Candidate	Target (Delivery)	Therapeutic Area	Discovery	IND enabling	Phase 1	Phase 2	Phase 3
Clinical Pipeline
NX-2127 Degrader	BTK + IKZF	B-cell malignancies
NX-5948 Degrader	BTK (Oral)	B-cell malignancies and autoimmune disease
NX-1607 Inhibitor	CBL-B (Oral)	Immuno-oncology
DeTIL-0255 Cell Therapy	Adoptive cell therapy with ex vivo CBL-B inhibition	Gynecologic malignancies
Drug Candidate	Target (Delivery)	Therapeutic Area	Discovery	IND enabling	Phase 1	Phase 2	Phase 3
Discovery Pipeline
Wholly Owned	Multiple targets*	Undisclosed
Gilead Sciences	5 targets	Undisclosed
Sanofi	5 targets	Undisclosed

Candidate / Target	Phase
Clinical Pipeline
NX-2127 Degrader BTK + IKZF	Phase 1
NX-5948 Degrader BTK (Oral)	Phase 1
NX-1607 Inhibitor CBL-B (Oral)	Phase 1
DeTIL-0255 Cell Therapy Adoptive cell therapy with ex vivo CBL-B inhibition	Phase 1
Discovery Pipeline
Wholly Owned Multiple targets*	Discovery
Gilead Sciences 5 targets	Discovery
Sanofi 5 targets	Discovery

Degraders and inhibitors of multiple targets including E3 ligases, T cell kinase, hematology & oncology drivers, and viral proteins